|
1.
Share Success: Letters From Readers
Letter
I: From D J Chavez, Albuquerque, New Mexico
Received
at sharesuccess @ ezorbonline.com Saturday, September 30, 2017 7:50 AM
(Unedited)
Three years ago, I had ordered your product Marvlix after reading about it researching herbs and natural supplements that would help me with my breathing illness problem ( COPD ).
Four years ago, I used to have to go to the VA's ER for severe breathing flare up every three to four weeks.
Any way, I ordered your Marvlix and was taking two to three capsules a day and it helped me so much I have not been to the ER since I started taking Marvlix till take two everyday.
My doctors all told me I was doing a lot better, looked good and was controlling my illness very well.
Ordering your product has prolong my life to live and continue a better quality of life as well. I live alone and in my sixties so I had to take better care of myself. Thank You for providing such a good product.
D J Chavez, Albuquerque, New Mexico
Letter
II: From Patricia S.
Received
at Testimonial
Submit Form Monday, October 23, 2017 4:15 PM
(Unedited)
I suffered with foot pain for a year and a half. Going to a foot Dr did not help and cost a lot. Figured I had nothing to lose by trying your product. Glad I did. Pain was gone in one month, and hasn't returned. Well worth the money.
Letter
III: From Lenna D.
Received
at Testimonial
Submit Form Friday, July 28, 2017 at 09:30:51
(Unedited)
Hi, my name is Lenna D. I began taking Ezorb about 4 years ago.
I was desperate to find a solution to my painful fingers. My husband is a medical doctor and diagnosed osteoporosis, for which there is little that can be done. I am a realtor and could barely hold the steering wheel of my car. Several of my fingers were swollen and two were black and blue.
I began taking Ezorb and within a month the swelling had gone down, and shortly after that the pain completely disappeared, and I have been pain free ever since. The only reminder that I had the condition is that some of my knuckles are enlarged. But I can live with that.
My husband now prescribes Ezorb to his patients.
Thank you for this amazing product and I will be a life long advocate.
Cheers
Lenna D.
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 95,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. If your testimonial is selected for publication, you will receive a gift to show
our appreciation of your effort.
2.
Research News: Statin Eligibility Associated With Increased Cancer Risk
Individuals eligible for statins according to the 2013 American College of Cardiology/American Heart Association (ACA/AHA) guidelines have a significantly increased risk for developing or dying of cancer compared with noneligible individuals, US researchers report.
Amit Pursnani (Northshore University Health System, Evanston, Illinois) and study co-authors say their findings suggest that "shared risk profiles and potential benefits of statins between cancer and cardiovascular outcomes may provide a unique opportunity to improve population health."
They report that, at a median 10 years of follow-up, incident cancer had been diagnosed in 11.2% of 2196 statin-naive individuals (mean age 50.5 years, 55% women) from the offspring and third-generation cohorts of the community-based longitudinal Framingham Heart Study.
The risk for cancer was a significant 80% higher among the 812 statin-eligible participants, with an incidence of 15.4%, than among the 1384 noneligible participants, at 8.8%.
Individuals eligible for statins, the guidelines for which are mainly based on a composite cardiovascular risk profile, rather than cholesterol level thresholds, also had a significant 12.1-fold increased risk for cancer mortality (4.2 vs 0.4%) and a 10.1-fold increased risk for noncardiovascular mortality (6.0 vs 0.7%) compared with those not eligible.
And when Pursnani and team stratified their data by age, body mass index, and smoking status, they observed similar results.
This "suggests that the association of cardiovascular risk with noncardiovascular outcomes is not driven by any one common causative risk factor in both cancer and [cardiovascular disease], but rather by the complex interplay of the several risk components that form the basis for determining statin eligibility, including age, blood pressure, cholesterol, smoking status, and diabetes," they write in the Journal of Clinical Oncology.
The researchers add: "The most important conclusion of our data is that there is an opportunity to improve public health awareness of shared risk factors for cardiovascular and cancer outcomes.
"If statin eligibility is, as our data suggest, not only an indicator of a higher risk of atherosclerotic cardiovascular disease but also of cancer incidence and mortality, the ACC/AHA guidelines present a unique and simple platform for identifying a cohort that is at a higher risk of cancer and cancer-related death," they conclude.
Original article appeared in 07-28-2017 | Oncology | News | Article.
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
